Skip to content

Testing for genetic changes in breast cancer

Genetic Screening of Epigenetic Modifiers in Newly Diagnosed Breast Cancer Patients. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075022
Enrollment
20
Registered
2024-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C501- Malignant neoplasm of central portion of breast Health Condition 2: C503- Malignant neoplasm of lower-innerquadrant of breast Health Condition 3: C505- Malignant neoplasm of lower-outerquadrant of breast Health Condition 4: C500- Malignant neoplasm of nipple and areola Health Condition 5: C508- Malignant neoplasm of overlappingsites of breast Health Condition 6: C502- Malignant neoplasm of upper-innerquadrant of breast Health Condition 7: C504- Malignant neoplasm of upp

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Intramural Fund, MAHE, Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed female breast cancer patients 2. Patients scheduled for Modified Radical Mastectomy (MRM) or Breast Conservative Surgery (BCS). 3. Patients who are willing to give informed consent. 4. Patients above the age of 18 years.

Exclusion criteria

Exclusion criteria: 1. Vulnerable patients 2. HIV, TB, Hepatitis positive patients.

Design outcomes

Primary

MeasureTime frame
1) Outcome measures used in this research comprise of demographic and clinical data, histopathology and diagnostic tests reports and descriptions of various treatment regimens used. 2) mRNA expressions of UHRF1 3) mRNA expressions of EZH2 4) mRNA expressions of UBL5 Timepoint: 3 Years

Secondary

MeasureTime frame
Correlating sociodemographic and clinicopathological parameters with the mRNA expressions of UHRF1, EZH2 and UBL5.Timepoint: 3 Years

Countries

India

Contacts

Public ContactDr Naveena AN Kumar

Manipal College of Pharmaceutical Sciences, MAHE, Manipal

mahadev.rao@manipal.edu8105706060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026